Skip to main content
. Author manuscript; available in PMC: 2015 Jan 13.
Published in final edited form as: Cancer Cell. 2014 Jan 13;25(1):37–48. doi: 10.1016/j.ccr.2013.12.004

Figure 1. Type I interferons are induced and necessary during antibody-mediated tumor regression.

Figure 1

A) WT BALB/c mice (n=4/group) were injected subcutaneously with 5×105 TUBO cells, then 100 μg of anti-Neu (left panel) or control IgG was administered on day 14. WT B6 mice (n=4/group) were injected subcutaneously with 7×105 B16-EGFR cells, then 100 μg of anti-EGFR (right panel) or control IgG was administered on day 14. Four days after the treatment, tumor was digested and sorted to CD45+ and CD45- population. Quantitive real-time PCR was performed to detect the expression of mRNA levels of mIFNα5. Mean + SD are shown. B) WT BALB/c mice (n=5/group) were injected subcutaneously with 5×105 TUBO-EGFR cells, then 100 μg of anti-Neu was administered on days 14 and 21. 200ug of anti-IFNAR or control Ig was intratumorally administrated on the same days. The growth of tumor was measured and compared twice a week. Mean + SEM are shown. C) WT B6 mice (n=5/group) were injected subcutaneously with 5×105 B16-EGFR cells, then 2×109 Adenovirus-IFNβ or control virus was intratumorally administrated on days 14 and 21. The growth of tumor was measured and compared twice a week. *, Mean + SEM are shown. p < 0.05 compared with control group. One representative experiment of three is depicted. See also Figure S1.